daily oral glp-1 receptor agonist orforglipron for adults with obesity pill delivers strong results treating diabetes and Orforglipron: Eli Lilly's New Oral
Description
Coutinho W, Halpern B
Respondents had an average age of 42.6 years and were 54.4% female, 45.1% male, and 0.5% nonbinary, representing all 50 states and the District of Columbia
Clinical uses Type 2 Diabetes Mellitus (T2DM) : Effective in lowering blood glucose without a significant risk of hypoglycemia
Perhaps Novo Nordisks most novel offering is a once-monthly ultrasound treatment for obesity, currently in early stages of exploration as part of a collaboration with GE Healthcare
Takashi Enjoji for digital PCR
doi: 10.3810/pgm.2012.11.2613
